Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Approved Drug Services In Europe
8 services found
Manufactured by:SAGA Diagnostics AB based inLund, SWEDEN
Today, we know much about the many mutations which can contribute to cancer, some mutations which can be inherited, as well as the many gene mutations which arise randomly and due to environmental exposures. Increasingly, these mutations can be targeted by approved drugs as well as dozens of therapeutics currently in development around the ...
by:Eurofins bioskin ( formely Bioskin GmbH) based inHamburg, GERMANY
The path to approval for generic topical products can be challenging. bioskin can help you to optimally plan and implement a development strategy: Vasoconstrictor assays according to FDA guidance: Bioequivalence of topical corticosteroids in Europe and the USA is assessed using the vasoconstrictor or human skin blanching assay as outlined in the FDA guidance. bioskin offers a competitive package ...
by:International Drug Development Institute (IDDI) based inLouvain-la-Neuve, BELGIUM
Aiming at optimizing your clinical development strategy, our expert consultants develop the innovative strategies and capabilities needed to launch products with the greatest potential for commercial success and improved patient outcomes. ...
by:Molecular Health GmbH based inHeidelberg, GERMANY
Act beyond human and experimental limitations. Knowledge to advance game-changing therapies from idea to market. The world's biomedical knowledge at your fingertips. Reliable predictions to anticipate risks. Interlinked data to find new targets and design novel drugs. Real-world evidence to evaluate success. These capabilities eliminate the uncertainties that limit drug development but are ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Acute Radiation Syndrome (ARS) involves severe, potentially lethal damage to the bone marrow’s ability to produce blood cells, as well as to other systems and organs. Severe damage to bone marrow makes victims vulnerable to life-threatening hemorrhage, infection and anemia. ...
Manufactured by:Soteria Medical BV based inArnhem, NETHERLANDS
Prostate cancer incidence rates rose dramatically in the late 1980s, when screening with the prostate-specific antigen (PSA) test, which received initial U.S. Food and Drug Administration approval in 1986, came into wide use. It is estimated that approximately $9.9 billion is spent each year in the United States on prostate cancer treatment. (National Cancer ...
Manufactured by:Micropore Technologies Ltd. based inRedcar,, UNITED KINGDOM
Commercialisation of sustained release formulations began in the 1970s with PLA & PGA used for surgical implants and sutures. PLGA (Poly (lactic acid-co-glycolic acid)) quickly emerged as the most important biocompatible, non-toxic polymer with numerous applications in drug delivery, tissue engineering, medical and surgical ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Bone marrow deficiency refers to a condition in which the hematopoietic stem cells in the bone marrow fail to produce enough, or produce abnormal, red blood cells, white blood cells and platelets. Hematopoietic cell transplantation (HCT), the transplantation of multipotent hematopoietic cells, is a standard treatment in various malignant and non-malignant conditions. Transplant patients are ...